RS20050420A - Prevention and treatment of alzheimer's disease - Google Patents

Prevention and treatment of alzheimer's disease

Info

Publication number
RS20050420A
RS20050420A YUP-2005/0420A YUP20050420A RS20050420A RS 20050420 A RS20050420 A RS 20050420A YU P20050420 A YUP20050420 A YU P20050420A RS 20050420 A RS20050420 A RS 20050420A
Authority
RS
Serbia
Prior art keywords
inhibitor
disease
alzheimer
prevention
treatment
Prior art date
Application number
YUP-2005/0420A
Other languages
English (en)
Inventor
Thierry Canton
Laurent Pradier
Jesus Benavides
Hubert HEUER
Hans Ludwig Schaefer
Original Assignee
Aventis Pharma S.A.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A., filed Critical Aventis Pharma S.A.,
Publication of RS20050420A publication Critical patent/RS20050420A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Pronalazak se odnosi na primenu inhibitora ponovne apsorpcije intestinalnih žučnih kiselina u cilju prevencije i lečenja Alzheimer-ove bolesti, po potrebi u kombinaciji sa inhibitorom HMG-CoA reduktaze, inhibitorom ponovne apsorpcije holesterola, inhibitorom biosinteze holesterola ili inhibitorom APP sekretaze.
YUP-2005/0420A 2002-12-12 2003-12-10 Prevention and treatment of alzheimer's disease RS20050420A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
PCT/FR2003/003654 WO2004062652A1 (fr) 2002-12-12 2003-12-10 Application et traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
RS20050420A true RS20050420A (en) 2007-04-10

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0420A RS20050420A (en) 2002-12-12 2003-12-10 Prevention and treatment of alzheimer's disease

Country Status (22)

Country Link
EP (1) EP1572174A1 (sr)
JP (1) JP2006514063A (sr)
KR (1) KR20050084250A (sr)
CN (1) CN1726016A (sr)
AR (1) AR042354A1 (sr)
AU (1) AU2003296802A1 (sr)
BR (1) BR0317280A (sr)
CA (1) CA2507945A1 (sr)
CO (1) CO5700712A2 (sr)
FR (1) FR2848452B1 (sr)
HR (1) HRP20050534A2 (sr)
MA (1) MA27500A1 (sr)
MX (1) MXPA05005556A (sr)
NO (1) NO20053341L (sr)
NZ (1) NZ540496A (sr)
PE (1) PE20040770A1 (sr)
PL (1) PL377110A1 (sr)
RS (1) RS20050420A (sr)
RU (1) RU2005121909A (sr)
TW (1) TW200503707A (sr)
WO (1) WO2004062652A1 (sr)
ZA (1) ZA200504656B (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
ZA200603165B (en) 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
AU2005210004B2 (en) 2004-02-05 2010-10-28 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2006050359A2 (en) 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
EP2015750A2 (en) 2006-04-28 2009-01-21 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
EP2937085B1 (en) * 2007-05-22 2019-07-10 Otsuka Pharmaceutical Co., Ltd. A medicament comprising a carbostyril derivative and donezepil for treating alzheimer's disease
CN107375932B (zh) 2011-10-28 2021-12-21 夏尔人类遗传性治疗公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
EA029581B1 (ru) * 2011-10-28 2018-04-30 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Применение ингибиторов рециркуляции желчных кислот для лечения холестатического заболевания печени или прурита

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
CA2104594C (en) * 1991-02-22 2004-05-11 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
AU3585397A (en) * 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
CA2311356C (en) * 1998-01-28 2004-07-13 Warner-Lambert Company Method for treating alzheimer's disease
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
WO2001056579A1 (en) * 2000-02-04 2001-08-09 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
KR20050084250A (ko) 2005-08-26
CA2507945A1 (fr) 2004-07-29
CO5700712A2 (es) 2006-11-30
NO20053341L (no) 2005-09-07
NZ540496A (en) 2008-04-30
BR0317280A (pt) 2005-11-08
PL377110A1 (pl) 2006-01-23
AU2003296802A1 (en) 2004-08-10
JP2006514063A (ja) 2006-04-27
ZA200504656B (en) 2006-08-30
RU2005121909A (ru) 2006-01-20
NO20053341D0 (no) 2005-07-08
PE20040770A1 (es) 2004-12-10
FR2848452B1 (fr) 2007-04-06
MXPA05005556A (es) 2005-07-26
TW200503707A (en) 2005-02-01
EP1572174A1 (fr) 2005-09-14
MA27500A1 (fr) 2005-08-01
AR042354A1 (es) 2005-06-15
CN1726016A (zh) 2006-01-25
HRP20050534A2 (en) 2006-11-30
WO2004062652A1 (fr) 2004-07-29
FR2848452A1 (fr) 2004-06-18

Similar Documents

Publication Publication Date Title
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
GB0223040D0 (en) Therapeutic compounds
IL160065A0 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AP2004003189A0 (en) Use of CETP inhibitors and optionally HMG COA reductase inhibitors and/or antihypertensive agents.
EP1638950A4 (en) CYCLOHEXYLGLYCIN DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE FOR THE TREATMENT OR PREVENTION OF DIABETES
MXPA01006467A (es) Combinaciones de inhibidores de trasnporte de acido biliar ileal y derivados de acido nicotinico para indicaciones cardiovasculares.
EP1583534A4 (en) 3-AMINO-4-PHENYLBUTANIC ACID DERIVATIVES AS DIPEPTIDYL-PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
AP2003002743A0 (en) Therapeutic combination of a cept inhibitor and atorvastatin
ZA200410011B (en) Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
HK1073313A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AP2004002951A0 (en) "Combination of Eplerenone and an HMG CoA Reductase Inhibitor".
AU2004208615B2 (en) Medicine for prevention of and treatment for arteriosclerosis and hypertension
PL377344A1 (pl) Lekarstwo do profilaktyki i leczenia miażdżycy tętnic i nadciśnienia
IL174536A0 (en) Therapeutic treatment
MY133332A (en) Pyrrolidone derivatives as maob inhibitors
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
NO20053341L (no) Hindring og behandling av Alzheimers sykdom.
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
TW200714280A (en) Novel method of treating hyperlipidemia
HK1080408A1 (en) Use of brimonidine in the treatment of dementia a nd parkinson
HK1083767A1 (en) Combined use of a fibrate and orlistat for the treatment of obesity
WO2004028456A3 (en) Method and composition for treating neurodegenerative disorders
AU2003282035A1 (en) Modulation of s6 kinase activity for the treatment of obestiy
AU2003287513A1 (en) INHIBITORS OF Beta-SECRETASE, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE OR MILD COGNITIVE IMPAIRMENT